MedWellAI (MWAI)
OTHER OTC:MWAI
Want to see MWAI full AI Analyst Report?
Top Page
MedWellAI
(OTC:MWAI)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.29
▼(-60.00% Downside)
Action:Reiterated
Date:05/20/26
The score is primarily weighed down by weak financial performance (volatile revenue, persistent large losses, ongoing cash burn, and negative equity). Technicals also remain bearish with price below all key moving averages and negative MACD, despite oversold RSI. Valuation provides limited support due to negative earnings and no indicated dividend yield.
Positive Factors
Recurring SaaS revenue model
A SaaS subscription model creates recurring revenue and customer stickiness, enabling predictable renewals and scalable unit economics if adoption stabilizes. Over 2-6 months this supports revenue visibility, upsell opportunities and operational leverage versus one-off sales.
Negative Factors
Severe persistent unprofitability
Deep, sustained net losses indicate the business is not yet generating economic profit. Such magnitude of unprofitability undermines reinvestment capacity, forces frequent capital raises, and increases execution risk for scaling products and sales over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring SaaS revenue model
A SaaS subscription model creates recurring revenue and customer stickiness, enabling predictable renewals and scalable unit economics if adoption stabilizes. Over 2-6 months this supports revenue visibility, upsell opportunities and operational leverage versus one-off sales.
Read all positive factors
MedWellAI (MWAI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.97M
Dividend YieldN/A
Average Volume (3M)4.51K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue Growth-5.68%
EPS Growth60.23%
CountryUS
Employees1
SectorFinancial
Sector Strength70
IndustryFinancial - Capital Markets
Share Statistics
EPS (TTM)-0.36
Shares Outstanding6,536,580
10 Day Avg. Volume2,376
30 Day Avg. Volume4,515
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.81
Price to Sales (P/S)3.42
P/FCF Ratio-2.17
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue3.99
Enterprise Value/Gross Profit4.70
Enterprise Value/Ebitda-1.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MedWellAI Business Overview & Revenue Model
Company Description
MedWellAI Inc., through its subsidiary, develops, acquires, operates, and invests in businesses. It provides AI-driven healthcare and wellness solutions. The company also offers a B2B e-commerce platform for distributing pharmaceutical products, p...
How the Company Makes Money
MedWellAI generates revenue through a combination of subscription-based software-as-a-service (SaaS) licenses, one-time implementation fees, and ongoing support or consultation services for its AI-powered healthcare platforms. The company partners...
MedWellAI Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 689.71K | 594.77K | 5.86M | 5.86M | 3.86M | 6.55M |
| Gross Profit | 585.91K | 586.67K | 1.93M | 1.93M | 1.16M | 931.01K |
| EBITDA | -2.65M | -2.87M | -8.61M | -21.59M | 1.07M | -21.59M |
| Net Income | -3.04M | -3.61M | -11.52M | -11.52M | -565.51K | -22.43M |
Balance Sheet | ||||||
| Total Assets | 549.87K | 805.50K | 3.94M | 6.59M | 16.28M | 13.36M |
| Cash, Cash Equivalents and Short-Term Investments | 223.22K | 401.31K | 57.81K | 258.00K | 490.28K | 2.10M |
| Total Debt | 600.30K | 604.27K | 500.00K | 500.00K | 385.44K | 19.15K |
| Total Liabilities | 7.61M | 3.14M | 7.81M | 7.10M | 5.69M | 4.40M |
| Stockholders Equity | -7.06M | -2.50M | -3.87M | -509.88K | 10.59M | 8.96M |
Cash Flow | ||||||
| Free Cash Flow | -861.21K | -937.55K | -4.13M | -3.73M | -9.88M | -19.90M |
| Operating Cash Flow | -861.21K | -935.31K | -4.13M | -3.43M | 55.45K | -1.57M |
| Investing Cash Flow | 247.90K | 1.19M | 4.17M | 4.17M | -2.27M | -9.12M |
| Financing Cash Flow | 0.00 | 0.00 | -243.15K | -243.15K | 604.92K | 12.78M |
MedWellAI Technical Analysis
Negative
0.72
Price Trends
0.39
Negative
0.43
Negative
0.51
Negative
Market Momentum
>-0.01
Positive
44.90
Neutral
57.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MWAI, the sentiment is Negative. The current price of 0.72 is above the 20-day moving average (MA) of 0.38, above the 50-day MA of 0.39, and above the 200-day MA of 0.51, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.90 is Neutral, neither overbought nor oversold. The STOCH value of 57.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MWAI.
MedWellAI Risk Analysis
MedWellAI disclosed 12 risk factors in its most recent earnings report. MedWellAI reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MedWellAI Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
49 Neutral | $59.93M | -13.09 | -4.47% | ― | 52.29% | -169.04% | |
42 Neutral | $12.94M | -2.07 | -147.57% | ― | 271.41% | -19.81% | |
41 Neutral | $1.97M | -1.21 | ― | ― | -5.68% | 60.23% | |
41 Neutral | $11.24M | ― | 83.74% | ― | ― | ― | |
41 Neutral | $10.43M | -0.06 | 129.66% | ― | -82.43% | -299.27% |
* Financial Sector Average
MWAI
MedWellAI
0.36
0.10
35.96%
NVNI
Nvni Group
1.07
-3.02
-73.84%
AIXI
Xiao-I Corp. ADR
10.99
-50.41
-82.10%
SPPL
Simpple Ltd.
2.84
-0.62
-17.92%
HIT
Health In Tech, Inc. Class A
1.01
0.36
55.38%
CSAI
Cloudastructure, Inc. Class A
0.51
-2.68
-84.04%
MedWellAI Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
MedWellAI Expands Series B Preferred Stock Authorization
Neutral
Apr 17, 2026
On April 16, 2026, MedWellAI, Inc. filed a Certificate of Amendment with the Nevada Secretary of State to modify the terms governing its Series B Convertible Preferred Stock. The amendment increases the designated and authorized Series B Convertib...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.